Navigation Links
Encorium Reports Second Quarter 2009 Financial Results

WAYNE, Pa., Aug. 24 /PRNewswire/ -- Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical companies, today announced its financial results for the second quarter ended June 30, 2009.

As previously announced, on July 16, 2009 the Company sold substantially all of the assets relating to its US line of business to Pierrel Research USA, Inc., the result of which the Company no longer has any employees or significant operations in the United States. Due to this sale, for the six months ended June 30, 2009 and 2008, the results of the U.S. business have been presented as discontinued operations in the Company's consolidated financial statements.

Net revenue for the second quarter of 2009 was $4.5 million, a decrease of 23.37% from $5.9 million for the second quarter of 2008. The decrease in net revenues was primarily attributable to unfavorable foreign currency fluctuations of $1.4 million for the three months ended June 30, 2009. The Company had a consolidated backlog at June 30, 2009 from continuing operations of $19.6 million which included approximately $4.8 million of new business wins in the first half of 2009 compared to a backlog of $23.5 million at June 30, 2008.

Direct expenses for the second quarter of 2009 were $3.4 million, or 76.3% of net revenues, compared to $3.8 million, or 64.2% of net revenues, for the comparable prior year period. The decrease in direct expenses was primarily the result of approximately $541,000 of favorable foreign currency fluctuations absorbed by the Company's European operations in the second quarter of 2009, partially offset by severance and other costs of $202 thousand.

Selling, general, and administrative expenses (SG&A) decreased by 12% to $2.2 million, or 49.9% of net revenue, for the three months ended June 30, 2009, compared to $2.5 million, or 43% of net revenue, for the three months ended June 30, 2008. The decrease in SG&A was due primarily to approximately $178 thousand of favorable currency fluctuations and reduction in staff and facility costs in the Company's U.S. operations, partially offset by higher professional fee associated with the sale of the U.S. business.

Depreciation and amortization expense decreased 61.25% to $93,000 for the three months ended June 30, 2009 from $240,000 for the three months ended June 30, 2009 primarily as a result of certain intangible assets acquired as part of the Encorium Oy (formerly Remedium) acquisition being fully amortized.

Loss from continued operations increased by $604,000 for the three months to $1.3 million or $(0.06) per diluted share for the second quarter of 2009, from a net loss of $665,000, or $(0.03) per diluted share in the second quarter of 2008.

Financial Position

Encorium's balance sheet at June 30, 2009 reflected cash and cash equivalents of $838,696 and stockholders' equity of $1.8 million. The Company's latest financials have been prepared on a going concern basis. As previously disclosed, Encorium's independent registered public accounting firm reported that the Company's audited consolidated financial statements for the fiscal year ended December 31, 2008, included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 27, 2009, contains a paragraph that indicates that, while the Company's financial statements have been prepared on a going concern basis, there is substantial doubt about its ability to continue as a going concern, and that no adjustments have been made to the financial statements that might result from the outcome of this uncertainty.

Update on Sale of Encorium Oy

On May 11, 2009, we announced that we had entered into a non-binding letter of intent to sell our wholly-owned subsidiary, Encorium Oy, to a U.S. based clinical research organization. The terms of the transaction have not been announced and are continuing to be negotiated between the parties. The closing of the sale is subject to the completion if due diligence, execution of definitive agreements and stockholder approval. In the event the sale of Encorium Oy is consummated, the Company will no longer have any operations and the Board of Directors intend to, subject to stockholder approval, adopt a plan to liquidate and dissolve the Company and distribute liquidation proceeds, if any, to the stockholders. We anticipate the transaction will not close until the fourth quarter of 2009.

In the event the sale of Encorioum Oy is not consummated, we anticipate that will be able to meet our cash requirements through June of 2010, assuming we are able to fully implement our current cost cutting initiatives, we are able to win additional contracts during fiscal 2009 and we are able to maintain our current customer contracts. If the sale of Encorium Oy is not consummated we will continue to seek strategic alternatives, including, but not limited to attempting to secure additional financing. Our ability to obtain additional financing in the future will depend in part upon prevailing capital market conditions, as well as conditions in our business and our operating results; and those factors may affect our efforts to arrange additional financing on terms that are satisfactory to us or at all. If we are unable to secure additional financing on terms acceptable to us and on a timely basis, we may significantly reduce our operating costs, which may include the cessation of operations in some countries or seek stockholder approval to liquidate and dissolve. Any decision to liquidate and dissolve the Company may occur at any point during or before the first quarter of 2010. It is unclear whether there would be funds available for distribution to our stockholders in these instances.

About Encorium Group, Inc.

Encorium Group, Inc. is a global clinical research organization specializing in the design and management of complex clinical trials and Patient Registries for the pharmaceutical, biotechnology and medical device industries. The Company's mission is to provide its clients with high quality, full-service support for their biopharmaceutical and medical device development programs. Encorium offers therapeutic expertise, experienced team management and advanced technologies. The Company has drug and biologics development as well as clinical trial experience across a wide variety of therapeutic areas such as infectious diseases, cardiovascular, vaccines, oncology, diabetes endocrinology/metabolism, gene therapy, immunology, neurology, gastroenterology, dermatology, hepatology, women's health and respiratory medicine. Encorium believes that its expertise in the design of complex clinical trials, its therapeutic experience and commitment to excellence, and its application of innovative technologies, offer its clients a means to more quickly and cost effectively move products through the clinical development process.

This press release contains forward-looking statements identified by words such as "estimate," "project," "expect," "intend," "believe," "anticipate" and similar expressions regarding the potential sale Encorium Oy and our expectations regarding the effects of such transactions. Those statements involve risks and uncertainties, and actual results could differ materially from those discussed. Factors that could cause or contribute to such differences include, but are not limited to: (i) the timing of the closing, if any, of the transactions; (ii) the completion to the purchaser's satisfaction of due diligence; (iii) the acquisition by us of a fairness opinion relating to the purchase price for the sale of Encorium Oy; (iv) our ability to negotiate definitive agreements with the Purchaser; (v) the possibility that the transaction may not close; and (vi) the risk that any distributions to stockholders in connection with the transactions will not result in a premium to, and could be less than, the current stock price.

Additional risks and uncertainties that could affect the Company's future operating results and financial condition generally include, without limitation: (i) the risk that we may not have sufficient funds to operate our business; (ii)our success in attracting new business and retaining existing clients and projects; (iii) the size, duration and timing of clinical trials we are currently managing may change unexpectedly; (iv) the termination, delay or cancellation of clinical trials we are currently managing could cause revenues and cash-on-hand to decline unexpectedly; (v) the timing difference between our receipt of contract milestone or scheduled payments and our incurring costs to manage these trials; (vi) outsourcing trends in the pharmaceutical, biotechnology and medical device industries; (vii) the ability to maintain profit margins in a competitive marketplace; (viii) our ability to attract and retain qualified personnel; (ix) the sensitivity of our business to general economic conditions; (x) other economic, competitive, governmental and technological factors affecting our operations, markets, products, services and prices; (xi) announced awards received from existing and potential customers are not definitive until fully negotiated contracts are executed by the parties; (xii) our backlog may not be indicative of future results and may not generate the revenues expected; and (xiii) uncertainties regarding the availability of additional capital and continued listing of our common stock on Nasdaq. You should not place undue reliance on any forward-looking statement. We undertake no obligation to publicly release the result of any revision of these forward-looking statements to reflect events or circumstances after the date they are made or to reflect the occurrence of unanticipated events. Please refer to the section entitled "Risk Factors" in the Company Annual Report on Form 10-K for the year ended December 31, 2008 and the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2009 for a more complete discussion of factors which could cause our actual results and financial position to change.

You should not place any undue reliance on these forward-looking statements which speak only as of the date of this press release. Additional information concerning factors that might affect our business or stock price which could cause actual results to materially differ from those in forward-looking statements is contained in Encorium Group's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2008 and other periodic reports under the Securities Exchange Act of 1934, as amended, copies of which are available upon request from Encorium Group's investor relations department.

                                ENCORIUM GROUP, INC

                        Three Months              Six Months
                            Ended                    Ended
                           June 30,                 June 30,
                             2009        2008         2009         2008

        Net revenue     $4,483,263   $5,917,591   $9,021,436  $11,320,070
         revenue           799,315    1,059,297    1,915,366    1,968,736
    Total Revenue        5,282,578    6,976,888   10,936,802   13,288,806

    Operating Expenses
        Direct           3,421,073    3,796,212    6,364,975    7,506,880
         expenses          799,315    1,059,297    1,915,366    1,968,736
        Selling, general
         administrative  2,238,562    2,546,593    4,320,868    4,800,827
        Depreciation and
         amortization       92,877      240,229      183,375      780,275
    Total Operating
     Expenses            6,551,827    7,642,331   12,784,584   15,056,718

    Loss from
     Operations         (1,269,249)    (665,443)  (1,847,782)  (1,767,912)

          Income             1,064        7,287       10,107       12,685
          Expense           (2,059)      (6,299)     (14,563)      (6,915)
    Net Interest
     Income                   (995)         988       (4,456)       5,770

    Other expense                -            -            -            -

    Net Loss from
     operations before
     Income Taxes       (1,270,244)    (664,455)  (1,852,238)  (1,762,142)

    Income Tax Expense
     (Benefit)                  11       54,766       (7,927)      68,896

    Net Loss from
     operations        $(1,270,255)   $(719,221) $(1,844,311) $(1,831,038)

    Net loss from
     operations           (674,416)    (726,230)    (295,580)  (1,621,793)

    Income Tax Expense
     (Benefit)                   -            -            -            -

    Net Loss           $(1,944,671) $(1,445,451) $(2,139,891) $(3,452,831)

    Weighted Average Common and Common Equivalent Shares Outstanding

    Basic               20,523,883   20,603,140   20,523,883   20,603,140
    Diluted             20,523,883   20,603,140   20,523,883   20,603,140

    Net Loss per
     Common Share
     Operations        $     (0.06)   $   (0.03) $     (0.09) $     (0.09)
     Operations        $     (0.03)   $   (0.04) $     (0.01) $     (0.08)

    Net Loss per
     Common Share      $     (0.09)   $   (0.07) $     (0.10) $     (0.17)

                                 ENCORIUM GROUP, INC
                             CONSOLIDATED BALANCE SHEET

                                               June 30,        December 31,
                                                 2009              2008
    Current Assets
       Cash and cash equivalents              $ 838,696        $5,705,818
       Investigator advances                          0         1,088,768
       Accounts receivable, less allowance
        of $0 and $97,000 for June 30, 2009
        and December 31, 2008, respectively   2,790,665         4,624,161
       Prepaid expenses and other               958,731         1,206,088
       Prepaid taxes                             46,117            28,290
       Costs and estimated earnings in
        excess of related billings on
        uncompleted contracts                 1,260,625         1,443,427
             Total Current Assets             5,894,834        14,096,552

    Property and Equipment, Net                 314,191         1,211,929

    Intangible Assets
       Goodwill                               1,361,520         1,366,269
       Other intangibles, Net                 3,579,665         3,733,517

       Other assets, including net
        assets held for sale of $2.7M         3,177,303           684,666

    Total Assets                            $14,327,513       $21,092,933

    Liabilities and Stockholders' Equity
    Current Liabilities
       Accounts payable                      $3,088,534        $3,624,071
       Accrued expenses                       2,799,343         3,004,627
       Deferred taxes                           272,676           206,173
       Obligations under capital leases          46,076            72,542
       Billings in excess of related costs
        and estimated earnings on
        uncompleted contracts                   938,013         3,307,347
       Customer advances                      1,563,833         5,297,000
             Total Current Liabilities        8,708,475        15,511,760

    Long Term Liabilities
       Obligations under capital leases          63,444           189,680
       Deferred taxes                           857,458           897,204
       Other liabilities, including
        liabilities held for sale of $2.6M    2,901,254           316,516
             Total Long Term Liabilities      3,822,156         1,403,400
    Total Liabilities                        12,530,631        16,915,160

    Stockholders' Equity
       Common stock,  $.001 par value
        35,000,000 shares authorized,
        20,834,004 shares issued and
        20,523,883 shares outstanding,
        respectively                             20,834            20,834
       Additional paid-in capital            32,495,771        32,417,250
       Additional paid-in capital warrants      905,699           905,699
       Accumulated deficit                  (32,916,484)      (29,737,430)
       Accumulated other comprehensive
        income                                2,017,751         1,298,109
         Less:                                2,523,571         4,904,462
          Treasury stock, at cost,
           310,121 shares                      (726,689)         (726,689)
             Total Stockholders' Equity       1,796,882         4,177,773

    Total Liabilities and
     Stockholders' Equity                   $14,327,513       $21,092,933

SOURCE Encorium Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
2. Encorium Reports Third Quarter 2008 Financial Results
3. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
4. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
5. Encorium Group Signs Approximately $2.0 Million of New Business Contracts
6. Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
7. Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team
8. Encorium Group Updates Expected Timeframe with Respect to the Sale of its U.S. Business
9. Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes
10. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
11. QMed, Inc. Reports July Medicare SNP Enrollments
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions ... over 5.5 million people each year. Especially those living in larger cities are affected ... based in one of the most pollution-affected countries globally - decided to take action. ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights ... (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
(Date:10/9/2017)... FL (PRWEB) , ... October 09, 2017 , ... The ... scheduled to broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. ... industry is faced with the challenge of how to continue to feed a growing ...
Breaking Biology Technology:
(Date:4/5/2017)... KEY FINDINGS The global market for stem ... 25.76% during the forecast period of 2017-2025. The rise ... growth of the stem cell market. Download ... The global stem cell market is segmented on the ... cell market of the product is segmented into adult ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, ... Hack the Genome hackathon at Microsoft,s headquarters ... two-day competition will focus on developing health and wellness ... Hack the Genome is the first ... tremendous. The world,s largest companies in the genomics, tech ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
Breaking Biology News(10 mins):